These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 32123287)
1. PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer. Li W; Zhu Y; Zhang K; Yu X; Lin H; Wu W; Peng Y; Sun J Exp Mol Med; 2020 Mar; 52(3):409-422. PubMed ID: 32123287 [TBL] [Abstract][Full Text] [Related]
2. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335 [TBL] [Abstract][Full Text] [Related]
3. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway. Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522 [TBL] [Abstract][Full Text] [Related]
4. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway. Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057 [TBL] [Abstract][Full Text] [Related]
5. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling. Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896 [TBL] [Abstract][Full Text] [Related]
7. FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. Hou J; Wang L PLoS One; 2012; 7(5):e36252. PubMed ID: 22590527 [TBL] [Abstract][Full Text] [Related]
8. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. Cui J; Guo Y; Wu H; Xiong J; Peng T Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427 [TBL] [Abstract][Full Text] [Related]
9. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy. Song J; Xu J; Guo J; Shang Y; Wang J; Wang T Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437 [TBL] [Abstract][Full Text] [Related]
10. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607 [TBL] [Abstract][Full Text] [Related]
11. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling. Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of HOXC11 by artesunate induces ferroptosis and suppresses ovarian cancer progression through transcriptional regulation of the PROM2/PI3K/AKT pathway. Li J; Feng L; Yuan Y; He T; Zou X; Su B; Liu K; Yang X World J Surg Oncol; 2024 Oct; 22(1):268. PubMed ID: 39380001 [TBL] [Abstract][Full Text] [Related]
13. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways. Li J; Liang X; Yang X Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480 [TBL] [Abstract][Full Text] [Related]
14. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Liu T; Fang Y; Zhang H; Deng M; Gao B; Niu N; Yu J; Lee S; Kim J; Qin B; Xie F; Evans D; Wang L; Lou W; Lou Z Cancer Res; 2016 Feb; 76(3):572-81. PubMed ID: 26676747 [TBL] [Abstract][Full Text] [Related]
15. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977 [TBL] [Abstract][Full Text] [Related]
16. MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. Wang T; Chen G; Ma X; Yang Y; Chen Y; Peng Y; Bai Z; Zhang Z; Pei H; Guo W Cell Death Dis; 2019 Feb; 10(3):153. PubMed ID: 30770779 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer. Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma. Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312 [TBL] [Abstract][Full Text] [Related]